Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Capital Expenditures: 2023-2024

Historic Capital Expenditures for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $2.6 million.

  • Inhibrx Biosciences' Capital Expenditures fell 95.95% to $10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $294,000, marking a year-over-year decrease of 95.12%. This contributed to the annual value of $2.6 million for FY2024, which is 43.46% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Capital Expenditures stood at $2.6 million for FY2024, which was down 43.46% from $4.6 million recorded in FY2023.
  • Over the past 5 years, Inhibrx Biosciences' Capital Expenditures peaked at $4.6 million during FY2023, and registered a low of $2.6 million during FY2024.
  • In the last 2 years, Inhibrx Biosciences' Capital Expenditures had a median value of $3.6 million in 2023 and averaged $3.6 million.
  • Data for Inhibrx Biosciences' Capital Expenditures shows a maximum YoY tumbled of 43.46% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Capital Expenditures (Yearly) stood at $4.6 million in 2023, then crashed by 43.46% to $2.6 million in 2024.